Loading
A phase 1/2 trial of ICP-723 in brain and spinal cord tumours, run by Beijing InnoCare Pharma Tech Co., Ltd., now recruiting.
Study of ICP-723 in Patients With Advanced Solid Tumors or Primary Central Nervous System Tumors is a phase 1/2 interventional study registered as NCT05745623 by Beijing InnoCare Pharma Tech Co., Ltd., with 70 participants planned, started 2022-12-27 and due to reach its primary completion in 2027-12-25. Interventions recorded: ICP-723.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares InnoCare Pharma and the tag pipeline.
Shares InnoCare Pharma and the tag pipeline.
Shares InnoCare Pharma and the tag pipeline.
Shares InnoCare Pharma and the tag pipeline.
Shares Brain and spinal cord tumours (all types) and the tag pipeline.
Shares Brain and spinal cord tumours (all types) and the tag pipeline.
Shares InnoCare Pharma and the tag pipeline.
Shares Brain and spinal cord tumours (all types) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/